Philips Respironics, Respiratory Drug Delivery Ltd, Chichester, United Kingdom.
J Aerosol Med Pulm Drug Deliv. 2010 Apr;23 Suppl 1(Suppl 1):S11-20. doi: 10.1089/jamp.2009.0792.
The in vitro characterization of device-related parameters such as the rate of aerosol output, total aerosol output, particle size, and fine particle fraction, is essential when assessing the potential performance of a nebulizer or making comparisons with other nebulizers as they are indicative of potential clinical performance. This article reviews a number of in vitro studies designed to characterize the I-neb Adaptive Aerosol Delivery (AAD) System in terms of drug delivery (particle size, residual, reproducibility, precise dose delivery, dose equivalence), in terms of drug-related performance (osmolality, surface tension, viscosity), and in terms of nebulizer orientation during operation. The results of the in vitro tests of drug delivery indicate that the I-neb AAD System is suitable for delivery of aqueous solutions by nebulization. The evaluation of equivalent doses between the I-neb AAD System (metered dose) and a conventional jet nebulizer (delivered dose), demonstrates that the amount of drug required to deliver the same dose is up to five times less with the I-neb AAD System due to the low residual and controlled drug delivery. The lack of change in osmolality during nebulization might be of importance as it presents an opportunity for delivery of drugs to patients with hyperreactive airways, or where a specific tonicity of the formulation is required. The physicochemical characteristics (surface tension, viscosity) of a number of drugs delivered with the I-neb AAD System highlights some of the demands created by existing and new drug formulations. Finally, the study of the impact of nebulizer orientation shows how important it is to also consider how the nebulizer will actually be physically used by the patient rather than solely under standard conditions used within the laboratory.
在评估雾化器的潜在性能或与其他雾化器进行比较时,对与设备相关的参数(如气溶胶输出率、总气溶胶输出量、颗粒大小和细颗粒分数)进行体外特性分析至关重要,因为这些参数可反映潜在的临床性能。本文回顾了一些旨在描述 I-neb 自适应气溶胶输送(AAD)系统的体外研究,这些研究涉及药物输送(颗粒大小、残留量、重现性、精确剂量输送、剂量等效性)、药物相关性能(渗透压、表面张力、粘度)和操作过程中的雾化器方向。药物输送的体外测试结果表明,I-neb AAD 系统适用于通过雾化输送水溶液。对 I-neb AAD 系统(计量剂量)和传统射流雾化器(输送剂量)之间等效剂量的评估表明,由于残留量低且药物输送得到控制,因此使用 I-neb AAD 系统输送相同剂量所需的药物量最多可减少五倍。在雾化过程中渗透压不变可能很重要,因为这为向高反应性气道的患者或需要特定配方渗透压的患者输送药物提供了机会。通过 I-neb AAD 系统输送的一些药物的理化特性(表面张力、粘度)突出了现有和新药物配方带来的一些需求。最后,对雾化器方向影响的研究表明,考虑患者实际使用雾化器的方式,而不仅仅是在实验室中使用的标准条件,是非常重要的。